Stock Price
94.73
Daily Change
0.71 0.76%
Monthly
-3.35%
Yearly
39.31%
Q1 Forecast
92.35

Date Reference Time Actual Consensus Previous
2026-04-27 FY2026Q1 AM 1.96 0.98
2026-03-23 FY2026Q4 AM 2.52 1.98 0.98
2025-10-24 FY2025Q3 AM 1.14 1.1 0.79
2025-07-28 FY2025Q2 AM 1.72 0.96 0.79
2025-04-28 FY2025Q1 AM 1.28 0.71 0.66



Peers Price Chg Day Year Date
Cspc Pharmaceutical 8.16 -0.33 -3.89% 65.85% Mar/26
Sino Biopharmaceutical 5.82 -0.11 -1.86% 59.45% Mar/26
Sh Fosun Pharma 25.29 -0.07 -0.28% 1.20% Mar/26
Jiangsu Hengrui 51.63 -2.47 -4.57% 6.70% Mar/26
Zhangzhou Pientzehuang Pharmaceutical 152.15 -1.92 -1.25% -26.19% Mar/26
Kangmei Pharma 1.74 -0.03 -1.69% -19.07% Mar/26
Sh Pharmaceutical 16.44 -0.14 -0.84% -15.35% Mar/26

Indexes Price Day Year Date
SHANGHAI 50 2825 -34.86 -1.22% 4.97% Mar/26

WuXi AppTec Co Ltd traded at 94.73 this Thursday March 26th, increasing 0.71 or 0.76 percent since the previous trading session. Looking back, over the last four weeks, WuXi AppTec gained 3.35 percent. Over the last 12 months, its price rose by 39.31 percent. Looking ahead, we forecast WuXi AppTec Co Ltd to be priced at 92.35 by the end of this quarter and at 86.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The Company conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.